Rhythm Pharmaceuticals(NASDAQ) RYTM

Rhythm helps people with rare genetic diseases that cause constant hunger and severe weight gain. The company makes medicines that fix signals in the brain to help manage food intake. These treatments serve patients who cannot control their appetite due to specific biological issues.

Fighting Hunger at the Source

• IMCIVREE: A daily injection designed to activate the MC4R pathway to reduce hunger and weight; it is the company's only approved product.
• Bivamelagon: An investigational oral pill currently in Phase 2 testing for patients with hypothalamic obesity.
• RM-718: A weekly injection in early-stage trials meant to treat rare obesity without changing skin color.

Expanding the Research Map

• Licensed bivamelagon from LG Chem in January 2024 to add an oral treatment option to the pipeline.
• Submitted a request to European regulators in early 2025 to update pediatric plans by focusing on newer drug candidates.
• Received orphan drug designation from Japan’s Ministry of Health, Labor and Welfare in March 2025 for treating hypothalamic obesity.
• Completed enrollment for a supplemental trial group of 12 patients in Japan in January 2025.

What Makes Rhythm Different

The company maintains a massive DNA database with 120,000 sequencing samples to find patients with rare genetic variants. Rhythm operates as a specialized commercial-stage business with teams in 11 countries outside of North America.

The Recent Financial Record

• Revenue reached $57.3 million in Q4 2025, up 36.9% from Q4 2024.
• Gross profit was $52.5 million in Q4 2025, up 37.9% year-over-year.
• Net loss widened to $47.5 million in Q4 2025, a 9.7% increase in losses from the previous year.
• Free cash flow was negative $26.3 million in Q4 2025, with cash use increasing 39.8% from the same period in 2024.

The Evolution of Rhythm

Rhythm has transitioned from a research firm into a global commercial business selling its first rare-disease therapy. The company continues to shift its focus toward next-generation oral and weekly medicines to reach more patients.